The present disclosure belongs to the field of biomedicine, and relates to use of DR-18 and an M1 virus in the preparation of an anti-tumor drug. The present disclosure first identifies a combination of the M1 virus and the DR-18 has synergistic anti-tumor effects. The present disclosure also relates to an anti-tumor drug composition including the M1 virus and the DR-18, as well as use of the M1 virus and the DR-18 in the preparation of an anti-tumor drug.
The present invention relates to use of DR-18 and herpes simplex virus in the preparation of an antitumor drug. It is found for the first time that the combination of herpes simplex virus and DR-18 has a synergistic antitumor effect. The present invention also relates to an antitumor pharmaceutical composition comprising herpes simplex virus and DR-18, and use of herpes simplex virus and DR-18 in the preparation of an antitumor drug.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Demonstration of goods; Import-export agency services; Business services, namely, combined strategic goods or services sourcing and cooperative purchasing for others; Marketing services; Wholesale store services for pharmaceutical, veterinary and sanitary preparations and medical supplies; Retail store services for pharmaceutical, veterinary and sanitary preparations and medical supplies; Advertising services in the field of pharmaceuticals; Pharmaceutical services, namely, processing online and telephone prescription orders in retail and central fill pharmacies; Advertising relating to pharmaceutical products and in-vivo imaging products; Business organization and management consulting Medicinal preparations for the treatment of infectious diseases and for use in oncology; Vaccines; Diagnostic agents, preparations and substances for medical purposes; Diagnostic biomarker reagents for medical purposes; Biological preparations for the treatment of cancer; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical preparations for suppressing tumors; Immunostimulants
05 - Produits pharmaceutiques, vétérinaires et hygièniques
35 - Publicité; Affaires commerciales
Produits et services
Medicinal preparations for the treatment of infectious diseases and for use in oncology; Vaccines; Diagnostic agents, preparations and substances for medical purposes; Diagnostic biomarker reagents for medical purposes; Biological preparations for the treatment of cancer; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical preparations for suppressing tumors; Immunostimulants Demonstration of goods; Import-export agency services; Business services, namely, combined strategic goods or services sourcing and cooperative purchasing for others; Marketing services; Wholesale store services for pharmaceutical, veterinary and sanitary preparations and medical supplies; Retail store services for pharmaceutical, veterinary and sanitary preparations and medical supplies; Advertising services in the field of pharmaceuticals; Pharmaceutical services, namely, processing online and telephone prescription orders in retail and central fill pharmacies; Advertising relating to pharmaceutical products and in-vivo imaging products; Business organization and management consulting
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Demonstration of goods; Import-export agency services; Business services, namely, combined strategic goods or services sourcing and cooperative purchasing for others; Marketing services; Wholesale store services for pharmaceutical, veterinary and sanitary preparations and medical supplies; Retail store services for pharmaceutical, veterinary and sanitary preparations and medical supplies; Advertising services in the field of pharmaceuticals; Pharmaceutical services, namely, processing online and telephone prescription orders in retail and central fill pharmacies; Advertising relating to pharmaceutical products and in-vivo imaging products; Business organization and management consulting Medicinal preparations for the treatment of infectious diseases and for use in oncology; Vaccines; Diagnostic agents, preparations and substances for medical purposes; Diagnostic biomarker reagents for medical purposes; Biological preparations for the treatment of cancer; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical preparations for suppressing tumors; Immunostimulants
6.
USE OF DR-18 AND ONCOLYTIC VACCINIA VIRUS IN PREPARATION OF ANTI-TUMOR DRUG
The present disclosure belongs to the field of biological medicines, and relates to use of DR-18 and an oncolytic vaccinia virus in the preparation of an anti-tumor drug. The present disclosure has found for the first time that combined use of the oncolytic vaccinia virus and DR-18 has a synergistic anti-tumor effect. The present disclosure also relates to an anti-tumor pharmaceutical composition comprising an oncolytic vaccinia virus and DR-18, and use of an oncolytic vaccinia virus and DR-18 in the preparation of an anti-tumor drug.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
35 - Publicité; Affaires commerciales
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Medicines for human purposes; medicinal drinks;
pharmaceutical preparations; injectable pharmaceuticals;
pharmaceutical tablets; antiseptics; disinfectants; dietetic
substances adapted for medical use; dietetic beverages
adapted for medical purposes; medicines for veterinary
purposes. Retail services for pharmaceutical, veterinary and sanitary
preparations and medical supplies; retail and wholesale
services for human medicines; retail and wholesale services
for pharmaceutical preparations; retail and wholesale
services for sanitary preparations; retail and wholesale
services for medical supplies. Technological research; quality assessment; chemical
research; bacteriological research; biological research;
material testing; chemical analysis; chemistry services;
scientific laboratory services; clinical trials. Medical clinic services; rest home services; health center
services; health counseling; therapy services; dietary and
nutritional advice; massage; animal breeding; gardening;
rental of sanitary installations.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
35 - Publicité; Affaires commerciales
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Medicines for human purposes for the treatment of cancer; medicinal drinks; pharmaceutical preparations for the treatment of cancer; injectable pharmaceuticals for the treatment of cancer; pharmaceutical tablets for the treatment of cancer; antiseptics; disinfectants; dietetic foods adapted for medical use; dietetic beverages adapted for medical purposes; medicines for veterinary purposes for the treatment of cancer Retail store services for pharmaceutical, veterinary and sanitary preparations and medical supplies; retail and wholesale store services for human medicines; retail and wholesale store services for pharmaceutical preparations; retail and wholesale store services for sanitary preparations; retail and wholesale store services for medical supplies Technological research in the technology field of biochemistry; quality assessment being quality control for others; chemical research; bacteriological research; biological research; material testing; chemical analysis; chemistry services, namely, research and development services in the field of chemistry; scientific laboratory services; scientific research in the nature of conducting clinical trials for others Medical clinic services; rest home services; health center services; health counseling; cognitive therapy services; providing dietary and nutritional advice; massage; animal breeding; gardening; rental of sanitary installations
9.
PHENOTHIAZINES AND THEIR DERIVATIVES FOR USE AS A MEDICAMENT
Disclosed is a new use of a phenothiazine compound in pharmacy, particularly in the preparation of a PD-1 signaling inhibitor, which is selected from the compounds represented by formula (I), their hydrates, solvates and reduced forms. The phenothiazine compounds disclosed herein inhibit the function of PD-1 and block the signal transduction of PD-1, so that they can be used as PD-1 signal transduction inhibitors. In vitro experiments found that these compounds can restore the function of immune cells inhibited by PD-1, thereby improving the function of CTL and other immune cells to secrete cytokines and kill target cells, enhancing the body's immune function and being effective in treating tumor.
A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p. ex. phénothiazine, chlorpromazine, piroxicam
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
Provided is an M1 virus. Further provided are a series of uses of said virus. The uses include, but are not limited to, viral vectors, anti-tumor agents, and pharmaceutical compositions. Said virus can effectively inhibit the growth of various tumor cells, and at the same time, has tumor targeting properties and is non-toxic to normal cells. Said virus can be administrated by means of intravenous injection, having operational convenience.
A novel application of a phenothiazine compound in pharmaceutics, the phenothiazine compound being selected from among a compound represented by formula (I), a hydrate, a solvate or a reduced form thereof. Specifically, the application is an application in the preparation of a PD-1 signal transduction inhibitor. The phenothiazine compound may inhibit the function of PD-1 and block the signal conduction of PD-1, so that the compound may be used as a PD-1 signal transduction inhibitor. In in vitro experiments, it was found that said type of compound can restore the function of immune cells inhibited by PD-1, thereby improving the function of immune cells, such as CTL, of secreting cytokines and killing target cells, thus improving the immune function of the body and effectively treating tumors.
A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p. ex. phénothiazine, chlorpromazine, piroxicam
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
Provided is an M1 virus. Further provided are a series of uses of said virus. The uses include, but are not limited to, viral vectors, anti-tumor agents, and pharmaceutical compositions. Said virus can effectively inhibit the growth of various tumor cells, and at the same time, has tumor targeting properties and is non-toxic to normal cells. Said virus can be administrated by means of intravenous injection, having operational convenience.
Disclosed is use of alphavirus in preparation of antitumor drugs. The alphavirus is M1 virus or Getah virus. In addition, the specific tumor types sensitive to abovementioned alphavirus treatment are further determined, so as to provide a safe and effective solution for antitumor drug administering schemes.
Use of a proteasome inhibitor and an alphavirus in the preparation of an anti-tumor medicament. The proteasome inhibitor can be used to prepare an alphavirus anti-tumor synergist. A pharmaceutical composition comprising a proteasome inhibitor and an alphavirus, including a pharmaceutical kit comprising the proteasome inhibitor and the alphavirus, and use of the proteasome inhibitor and the virus in the treatment of tumors, particularly tumors insensitive to the alphavirus.
Disclosed is the use of an aurora kinase inhibitor and an alphavirus in preparing an anti-tumor drug. The aurora kinase inhibitor can be used in preparing an alphavirus anti-tumor synergist. Disclosed are a pharmaceutical composition containing the aurora kinase inhibitor and the alphavirus, a drug kit containing the aurora kinase inhibitor and the alphavirus, and the use of the aurora kinase inhibitor and the alphavirus in treating tumors, especially those that are insensitive to the alphavirus.
Disclosed is the use of a mevalonate metabolic pathway inhibitor and an alphavirus in preparing an anti-tumor drug. The mevalonate metabolic pathway inhibitor can be used in preparing an alphavirus anti-tumor synergist. Disclosed are a pharmaceutical composition containing the mevalonate metabolic pathway inhibitor and the alphavirus, a drug kit containing the mevalonate metabolic pathway inhibitor and the alphavirus, and the use of the mevalonate metabolic pathway inhibitor and the alphavirus in treating tumors, especially those that are insensitive to the alphavirus.
An application of a CDK inhibitor and an oncolytic virus in the preparation of an antitumor drug. A CDK inhibitor can be used in the preparation of an oncolytic virus-based antitumor potentiator. Provided are a pharmaceutical composition comprising the CDK inhibitor and the oncolytic virus, a drug kit comprising the CDK inhibitor and the oncolytic virus, and a use of the CDK inhibitor and the oncolytic virus in the treatment of tumors, particularly the tumors not sensitive to the oncolytic virus.
Disclosed is the use of a PARP inhibitor and an oncolytic virus in preparing an anti-tumor drug. The PARP inhibitor can be used in preparing an oncolytic virus anti-tumor synergist. Disclosed are a pharmaceutical composition containing the PARP inhibitor and the oncolytic virus, a drug kit containing the PARP inhibitor and the oncolytic virus, and the use of the PARP inhibitor and the oncolytic virus in treating tumors, especially those that are insensitive to the oncolytic virus.
An application of an E3 ligase inhibitor and an oncolytic virus in preparing an anti-tumor drug, wherein the E3 ligase inhibitor may be used to prepare an oncolytic virus anti-tumor synergist; a pharmaceutical composition comprising an E3 ligase inhibitor and an oncolytic virus, a pharmaceutical kit comprising an E3 ligase inhibitor and an oncolytic virus, and a use of an E3 ligase inhibitor and an oncolytic virus in treating tumors, in particular tumors that are insensitive to the oncolytic virus.
The present invention belongs to the field of biomedicine and relates to use of VCP (valosin-containing protein, VCP) inhibitor and oncolytic virus in the preparation of an anti-tumor drug. The present invention firstly discovers that VCP inhibitor can be used in the preparation of an anti-tumor synergist for oncolytic virus. Meanwhile, the present invention relates to a pharmaceutical composition comprising VCP inhibitor and oncolytic virus, a pharmaceutical kit comprising VCP inhibitor and oncolytic virus, and use of VCP inhibitor and oncolytic virus for treating tumor, especially a tumor that is not sensitive to oncolytic virus. The present invention also relates to an anti-tumor administration system, characterized in that, comprising oncolytic virus and a reagent for detecting the expression level of VCP.
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
A61K 31/4178 - 1,3-Diazoles non condensés et contenant d'autres hétérocycles, p. ex. pilocarpine, nitrofurantoïne
A61K 35/768 - Virus oncolytiques non prévus dans les groupes
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
21.
USE OF VCP INHIBITOR AND ONCOLYTIC VIRUS IN THE PREPARATION OF AN ANTI-TUMOR DRUG
Use of VCP (valosin-containing protein, VCP) inhibitor and oncolytic virus in the preparation of an anti-tumor drug. The present invention firstly discovers that VCP inhibitor can be used in the preparation of an anti-tumor synergist for oncolytic virus. Meanwhile, a pharmaceutical composition comprising VCP inhibitor and oncolytic virus, a pharmaceutical kit comprising VCP inhibitor and oncolytic virus, and use of VCP inhibitor and oncolytic virus for treating tumor. The present invention discloses an anti-tumor administration system, characterized in that, comprising oncolytic virus and a reagent for detecting the expression level of VCP.
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61K 35/768 - Virus oncolytiques non prévus dans les groupes
Described herein is use of a Caspase activator and an oncolytic virus in the preparation of an anti-tumor drug. As described, Caspase activator can enhance the anti-tumor effect of oncolytic virus, and the combination of Caspase activator and oncolytic virus produces a significant synergistic anti-tumor effect, and demonstrates an effective therapy for the treatment of tumors that are less sensitive to other pharmaceutical treatments.
The use of Bcl-xL inhibitor and oncolytic virus in the preparation of an anti-tumor drug is disclosed. Bcl-xL inhibitor can be used as an anti-tumor synergist for oncolytic virus. A pharmaceutical composition comprising Bcl-xL inhibitor and oncolytic virus, a pharmaceutical kit comprising Bcl-xL inhibitor and oncolytic virus, and use of Bcl-xL inhibitor and oncolytic virus for treating tumors are also disclosed.
Disclosed is use of alphavirus in preparation of antitumor drugs. The alphavirus is M1 virus or Getah virus. In addition, the specific tumor types sensitive to abovementioned alphavirus treatment are further determined, so as to provide a safe and effective solution for antitumor drug administering schemes.
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
A61K 35/768 - Virus oncolytiques non prévus dans les groupes
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
25.
APPLICATION OF CHRYSOPHANOL OR ITS DERIVATIVES AND ONCOLYTIC VIRUS IN PREPARING ANTI-TUMOR DRUGS
The present invention relates to the field of biological medicine and discloses an application of chrysophanol or its derivatives and oncolytic virus in preparing antitumor drugs. It is found for the first time that the chrysophanol or its derivatives can be used to prepare a synergistic agent with oncolytic virus in terms of anti-tumor effects. Also disclosed are a pharmaceutical composition comprising chrysophanol and oncolytic virus, a pharmaceutical package comprising chrysophanol and oncolytic virus, and the use of chrysophanol and oncolytic virus in treating tumors, in particular tumors insensitive to oncolytic virus.
Disclosed are a pharmaceutical composition containing a direct or indirect agonist of Epac and an oncolytic virus, medication set, and the use thereof in the preparation of medication for treating tumors, in particular, tumors insensitive to the oncolytic virus. Also disclosed is a method of producing an oncolytic virus in-vitro.
Disclosed is use of alphavirus in preparation of antitumor drugs. The alphavirus is M1 virus or Getah virus. In addition, the specific tumor types sensitive to the abovementioned alphavirus treatment are further determined, so as to provide a safe and effective solution for antitumor drug administering schemes.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
28.
USE OF ALPHAVIRUS IN PREPARATION OF ANTITUMOR DRUGS
Disclosed is use of alphavirus in preparation of antitumor drugs. The alphavirus is M1 virus or Getah virus. In addition, the specific tumor types sensitive to the abovementioned alphavirus treatment are further determined, so as to provide a safe and effective solution for antitumor drug administering schemes.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
